Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth. LLY trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential to $1,492.70 for patient investors amid ongoing consolidation. Combined with the planned capacity expansions and the promising FY2026 guidance, LLY offers rich upside potential upon Orforglipron's upcoming US FDA approval/commercial launch. NVO is downgraded to Hold, given the disappointing FY 2026 guidance despite the tailwinds from the oral Wegovy launch and their first mover advantage. Barring an acceleration in its adj. EPS growth prospects and/or the upward re-rating in its valuations, NVO presents a potential value trap thesis here. Alones Creative/iStock via Getty Images I previously compared Eli Lilly and Company ( LLY ) and Novo Nordisk A/S ( NVO NONOF ) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered t
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Daiwa Securities Group Inc. from $1,230.00 to $1,250.00. They now have a "buy" rating on the stock.MarketBeat
- Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study [CNBC]CNBC
- Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPR Newswire
- Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and CompanyBusiness Wire
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website